<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610203</url>
  </required_header>
  <id_info>
    <org_study_id>CPS 18-439</org_study_id>
    <secondary_id>pfact 9806</secondary_id>
    <nct_id>NCT04610203</nct_id>
  </id_info>
  <brief_title>Glycaemic Response, Insulinaemic Response, GLP-1 and GIP Testing of Food Product Lines</brief_title>
  <official_title>Glycaemic, Insulinaemic, Gastric Inhibitory Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Response for Glucose, Glucose With 25 g Nutralys S85 Plus and Glucose With 50 g Nutralys S85 Plus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxford Brookes University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roquette Freres</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oxford Brookes University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to compare the glycaemic response, insulinaemic response, GIP&#xD;
      response and GLP-1 response to glucose, 25 g Nutralys S85 Plus and 50 g Nutralys S85 Plus&#xD;
      using a single-blind, randomised, repeat measure, crossover design trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of this study were to examine:&#xD;
&#xD;
        -  Phase I - the glycaemic response (GR) and insulinaemic response (IR) to:&#xD;
&#xD;
             -  50 g available carbohydrate&#xD;
&#xD;
             -  50 g available carbohydrate + protein (dose 1)&#xD;
&#xD;
             -  50 g available carbohydrate + protein (dose 2)&#xD;
&#xD;
        -  Phase II - the GLP-1 and GIP response to:&#xD;
&#xD;
             -  50 g available carbohydrate&#xD;
&#xD;
             -  50 g available carbohydrate + protein (dose 1)&#xD;
&#xD;
             -  50 g available carbohydrate + protein (dose 2)&#xD;
&#xD;
      A single-blind, randomised, repeat measure, crossover design trial was used to study the&#xD;
      response following consumption of three meals: one reference meal (50 g available&#xD;
      carbohydrate) and two test meals (50 g available carbohydrate with protein dose 1 and 50 g&#xD;
      available carbohydrate with protein dose 2). The study was conducted in two phases:&#xD;
&#xD;
        -  Phase I: glycaemic response (GR), insulinaemic response (IR)&#xD;
&#xD;
        -  Phase II: GLP-1 response and GIP response&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">July 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomised, repeat measure, crossover design trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>single-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood glucose response from baseline for 3 hours</measure>
    <time_frame>3 hours</time_frame>
    <description>Change in postprandial blood glucose response from baseline was measured at 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma insulin response from baseline for 3 hours</measure>
    <time_frame>3 hours</time_frame>
    <description>Change in postprandial plasma insulin response from baseline was measured at 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the blood glucose concentration versus time curve</measure>
    <time_frame>3 hours</time_frame>
    <description>Area under the blood glucose concentration versus time curve was calculated by trapezoidal rule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma insulin concentration versus time curve</measure>
    <time_frame>3 hours</time_frame>
    <description>Area under the plasma insulin concentration versus time curve was calculated by trapezoidal rule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak blood glucose concentration (Cmax)</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Peak blood glucose concentration (Cmax) after consumption of the test food</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma insulin concentration (Cmax)</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Peak plasma insulin concentration (Cmax) after consumption of the test food</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of blood glucose peak (Tmax)</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Time of blood glucose peak after consumption of the test food</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of plasma insulin peak (Tmax)</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Time of plasma insulin peak after consumption of the test food</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in GLP-1 from baseline for 3 hours</measure>
    <time_frame>3 hours</time_frame>
    <description>Change in GLP-1 from baseline was measured at 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GIP from baseline for 3 hours</measure>
    <time_frame>3 hours</time_frame>
    <description>Change in GIP from baseline was measured at 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma GLP-1 concentration versus time curve</measure>
    <time_frame>3 hours</time_frame>
    <description>Area under the plasma GLP-1 concentration versus time curve was calculated by trapezoidal rule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma GIP concentration versus time curve</measure>
    <time_frame>3 hours</time_frame>
    <description>Area under the plasma GIP concentration versus time curve was calculated by trapezoidal rule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma GLP-1 concentration (Cmax)</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Peak plasma GLP-1 concentration (Cmax) after consumption of the test food</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma GIP concentration (Cmax)</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Peak plasma GIP concentration (Cmax) after consumption of the test food</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of plasma GLP-1 peak (Tmax)</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Time of plasma GLP-1 peak after consumption of the test food</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of plasma GIP peak (Tmax)</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Time of plasma GIP peak after consumption of the test food</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Glucose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Glucose - 50 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutralys S85 Plus 25 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutralys S85 Plus Pea Protein 25 g + 50 g Glucose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutralys S85 Plus 50 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutralys S85 Plus Pea Protein 50 g + 50 g Glucose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>25 g Nutralys Pea Protein</intervention_name>
    <description>To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose +25g Nutralys S85 Plus</description>
    <arm_group_label>Nutralys S85 Plus 25 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>50 g Nutralys S85 Plus.</intervention_name>
    <description>To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose+50 g Nutralys S85 Plus .</description>
    <arm_group_label>Nutralys S85 Plus 50 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>50 g Glucose</intervention_name>
    <description>To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose</description>
    <arm_group_label>Glucose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 60 years&#xD;
&#xD;
          -  Body mass index (BMI) less than 30kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Fasting blood glucose value &gt; 6.1 mmol/l&#xD;
&#xD;
          -  Any known food allergy or intolerance&#xD;
&#xD;
          -  Medical condition(s) or medication(s) known to affect glucose regulation or appetite&#xD;
             and/or which influence digestion and absorption of nutrients&#xD;
&#xD;
          -  Known history of diabetes mellitus or the use of antihyperglycaemic drugs or insulin&#xD;
             to treat diabetes and related conditions&#xD;
&#xD;
          -  Major medical or surgical event requiring hospitalization within the preceding 3&#xD;
             months&#xD;
&#xD;
          -  Use of steroids, protease inhibitors or antipsychotics (all of which have major&#xD;
             effects on glucose metabolism and body fat distribution).&#xD;
&#xD;
          -  Unable to comply with experimental procedures or did not follow GR testing safety&#xD;
             guidelines.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sangeetha Thondre, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford Brookes University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oxford Brookes Centre for Nutrition and Health</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 0BP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.iso.org/standard/43633.html</url>
    <description>23. Food Products-Determination of the glycaemic index (GI) and recommendation for food classification.</description>
  </link>
  <reference>
    <citation>Siahanidou T, Margeli A, Kappis A, Papassotiriou I, Mandyla H. Circulating visfatin levels in healthy preterm infants are independently associated with high-density lipoprotein cholesterol levels and dietary long-chain polyunsaturated fatty acids. Metabolism. 2011 Mar;60(3):389-93. doi: 10.1016/j.metabol.2010.03.002. Epub 2010 Mar 31.</citation>
    <PMID>20359723</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 10, 2020</study_first_submitted>
  <study_first_submitted_qc>October 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oxford Brookes University</investigator_affiliation>
    <investigator_full_name>Dr. Sangeetha Thondre</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://drive.google.com/drive/folders/1H_y4bMle13r4wOG8YyapreznKUFG8cT_</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>http://drive.google.com/drive/folders/1H_y4bMle13r4wOG8YyapreznKUFG8cT_</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://drive.google.com/drive/folders/1H_y4bMle13r4wOG8YyapreznKUFG8cT_</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://drive.google.com/drive/folders/1H_y4bMle13r4wOG8YyapreznKUFG8cT_</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>http://drive.google.com/drive/folders/1H_y4bMle13r4wOG8YyapreznKUFG8cT_</doc_url>
      <doc_comment>Included in the Study Protocol and Clinical Study report</doc_comment>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT04610203/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT04610203/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

